Table 3.

Unadjusted Incidence of Fracture and Monthly Costs, by Treatment Group.

	Bisphosphonates	Teriparatide	P-Value
Clinical outcomes - no. patients (%)
Any fracture	5727 (14.5)	127 (23.09)	<0.001
Hip fracture	1596 (4.04)	31 (5.64)	0.059
Vertebral fracture	1421 (3.60)	43 (7.82)	<0.001
Fracture of radius, ulna or carpal bones	963 (2.44)	24 (4.36)	0.004
Other upper limb fractures	1132 (2.87)	21 (3.82)	0.185
Other lower limb fractures	2074 (5.25)	35 (6.36)	0.246
Monthly osteoporosis-related costs - (~)
Medical costs	12. 21	30. 25	<0.001
Pharmacy costs	19.24	318.00	<0.001
Total costs	31.45	348.25	<0.001

NOTES:

The unadjusted incidence of fracture was obtained as the percentage of study participants in each group experiencing the clinical outcome during follow-up period. Monthly medical costs were calculated as the monthly average of the total payment amount for all medical claims with primary or secondary ICD-9 codes for osteoporosis or fracture during follow-up period. Monthly pharmaceutical costs were calculated as the monthly average of the gross cost of prescriptions for either bisphosphonates or teriparatide during follow-up period. Total monthly costs were calculated as the sum of monthly medical and pharmaceutical costs. The estimates for the average medical costs are only ~25.14 and ~42.66 because 42% of our study participants had zero monthly medical costs during all follow-up period. These estimates are consistent with previous studies.(19)